InvestorsHub Logo
Followers 63
Posts 1756
Boards Moderated 0
Alias Born 09/21/2016

Re: None

Friday, 01/05/2018 2:13:13 PM

Friday, January 05, 2018 2:13:13 PM

Post# of 462661
Could I call your attention to this SA article today:

AveXis volatile after update on lead candidate AVXS-101http://www.seekingalpha.com/news/3321460

This;
(From the summary)

“The selling was apparently stoked by perceptions that its timeline for filing a U.S. marketing application for spinal muscular atrophy (SMA) Type 1 could be delayed.”

Apparently, the FDA required further information on the Ph3 trial and the back and forth which I speculated was happening between Anavex and the FDA, just as with the USPTO, and all regulatory bodies, is NOT CONFINED to Anavex, nor its leadership. It’s a fact of life that no one cares to mention - bureaucracies are NOT GOOD but they have good intentions*.


Just wanted to cite a current example from a Big Pharma to show that our company is not inept and our science/compounds are not snakebit. It’s a process. Roll with the punches.

We’ll get there. We are getting there.

Interesting to read the final remark in the comment section...seems I’ve heard that somewhere before?

GLTA
Bio
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News